Using probiotics to address weight gain from antipsychotic medications
Official title: A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Run by University College Cork · NCT06729671 · Data updated 2026-11-12
This study is testing whether a specific probiotic can help people with psychosis who are gaining weight from their antipsychotic medications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | University College Cork Academic / other |
| Locations | 2 sites (Cork and 1 other locations) |
| Status | Recruiting |
| Started | May 16, 2024 |
| Main results expected | November 30, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | December 11, 2024 |
| Trial ID | NCT06729671 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with a diagnosis of functional psychosis who are currently on antipsychotic medication.
✕Probably not a fit
Patients with a history of intravenous drug use or substance dependence in the past three months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of a specific probiotic, Bifidobacterium longum APC1472, to mitigate weight gain and metabolic dysfunction caused by antipsychotic medications in individuals diagnosed with psychosis. Participants aged 18-65 will be enrolled and will provide blood, saliva, and fecal samples to assess the impact of the probiotic on their metabolic health. The study aims to explore how modifying gut microbiota can alleviate the side effects of antipsychotic treatment, potentially improving adherence to medication and overall quality of life. The research is conducted at multiple locations in Cork, Ireland.
Why it matters
Potential benefit: If successful, this approach could significantly reduce weight gain and metabolic issues in patients taking antipsychotic medications, enhancing their overall health and medication adherence.
How similar studies have gone: Previous studies have shown promising results with probiotics in managing weight gain in animal models, suggesting potential for success in human applications.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 8.1 Inclusion Criteria To be considered eligible for enrolment into the study, subjects must; 1. Aged between 18-65 years old including women of child-bearing age 2. Having a diagnosis of affective or non-affective functional psychosis defined according to ICD-10 criteria for psychosis (codes F20-30 \& F32.3) 3. Patients who are able to and have given written informed consent 4. Patients who are willing to provide blood samples 5. Patients who are willing to provide saliva (cortisol) and faecal microbiome samples 6. Considering the nature of the study participants, a broad spectrum of concomitant medication will be permissible. Psychotropic meds, including antidepressants, mood stabilisers (lithium, valproate, carbamazepine), hypnotics and benzodiazapines, will be allowed as to not limit recruitment of this type of study participant. Exclusion Criteria: 1. Intravenous drug use 2. Diagnosis of substance dependence in the past 3 months 3. Pregnancy or planning a pregnancy 4. Antibiotic use in the past 30 days 5. Steroid use in the past 30 days 6. Use of anti-coagulants, anti-inflammatory drugs, over-the counter non-steroidal anti-inflammatories (NSAIDS) and analgesics. Subjects should have a wash-out period of 4 weeks. 7. Patients suffering from any clinically significant or unstable medical condition, including congestive heart failure, coeliac disease, or an immunodeficiency syndrome. 8. Pre or probiotic supplements within the past 30 days.
Where it's running
-
EIST clinics at St Mary's Primary Care Centre, Gurraunabraher & St Michaels In-Patient unit in the Mercy.
Cork, Ireland Recruiting -
RISE Metabolic Monitoring Clinics
Cork, Ireland Recruiting
Study contacts
- Principal investigator: Harriet Schellekens, PhD — University College Cork
- Study coordinator: Harriet Schellekens, PhD
- Email: H.schellekens@ucc.ie
- Phone: + 353 (0) 21 420 5429
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
State Representation in Early Psychosis 2
This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.
-
Recovery-oriented suicide prevention for young people at clinical high risk for psychosis
This program tests a peer-supported, clinician-led suicide prevention group for young people at clinical high risk for psychosis to see if it helps reduce suicidal thoughts and support recovery.
-
Combined brain stimulation and yoga for improving cognition in psychosis
This study tests whether active brain stimulation plus yoga can improve thinking skills and daily function in adults with psychosis.
-
See if an early-detection program reduces time to treatment for first-episode psychosis
We test whether a large, region-wide early-detection program can shorten the time from first psychotic symptoms to treatment and help people function better later.
-
Cerebellar imaging markers to predict antipsychotic response in first-episode psychosis
This will test whether cerebellar brain scans can predict how people with first-episode psychosis respond to 12 weeks of treatment with risperidone or aripiprazole.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.